
Editorial

iMed: A Global Academic Platform for Innovation, Medical Research and Translation

Chunlin Shao *

Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China

* Corresponding author. E-mail: clshao@shmu.edu.cn (C.S.)

Received: 22 October 2025; Accepted: 22 October 2025; Available online: 22 October 2025



© 2025 The authors. This is an open access article under the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>).

In an era where medical science is evolving at an unprecedented pace, the need for a dedicated platform that bridges fundamental discovery, translational innovation, and clinical application has never been more urgent. Today, we are proud to launch iMed, a peer-reviewed journal committed to showcasing high-impact research that pushes the boundaries of medical science across diverse disciplines. Our mission is to foster cross-pollination of ideas, accelerate knowledge translation, and ultimately drive progress in improving human health.

iMed's scope encompasses a broad spectrum of cutting-edge medical research, with a particular focus on interdisciplinary integration. In radiation medicine and science, we welcome work spanning radiobiology, advanced radiotherapy, nuclear pharmacy, and radioprotection. For oncology research, we cover tumor biology, microenvironment, metabolism, metastasis, and preclinical models, providing a venue for breakthroughs that unravel the complexities of cancer and inform novel therapeutic strategies.

Therapeutic innovation stands at the core of iMed's focus. We actively seek research on chemotherapy, targeted therapy, immunotherapy, gene therapy, and cell therapy, as well as the development of nanodrugs, intelligent drug delivery systems, and antibody-drug conjugates (ADCs), all of which are transforming precision medicine. In medical imaging, we embrace advancements in molecular imaging, multi-modality fusion, and image-guided intervention, recognizing their pivotal role in diagnosis and personalized treatment planning.

Frontier interdisciplinary research is a key highlight of iMed. We are dedicated to featuring work at the intersection of AI and medicine, medical big data analytics, systems biology, multi-omics technologies, and organoid research, reshaping how we understand disease mechanisms and develop therapies. Additionally, we cover basic medical sciences such as molecular and cellular biology, immunology, and regenerative medicine, as well as public health, epidemiology, and special environmental biology, ensuring a comprehensive view of medical progress.

iMed is more than just a journal. It is a community where researchers, clinicians, and innovators can connect and collaborate. We welcome original research articles, authoritative reviews, clinical trial reports, commentaries, and perspectives that meet our rigorous scientific standards. By curating diverse, high-quality content, we aim to facilitate knowledge exchange between basic and clinical researchers, accelerate the translation of preclinical discoveries to clinical practice, and address unmet medical needs worldwide.

We invite scientists and clinicians from across the globe to join us in this journey. Submit your groundbreaking work to iMed, and let us together build a platform that drives medical innovation forward. With a commitment to excellence, integrity, and interdisciplinary collaboration, iMed is poised to become a leading voice in shaping the future of medical research and translation.

Declaration of Competing Interest

The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.